Stock listing
PRLD Stock Price, News, Filings & Events — Prelude Therapeutics Incorporated
Selected listing: PRLD · NASDAQ · USD · US
This page tracks Prelude Therapeutics Incorporated's PRLD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PRLD:NASDAQ. PRLD:NASDAQ is the stock-level entry point for investors researching Prelude Therapeutics Incorporated, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Prelude Therapeutics Incorporated, trading under the ticker PRLD, is a public company based in the United States with a market capitalization of approximately $305 million. The company focuses on developing innovative therapies for cancer treatment. Prelude Therapeutics is committed to advancing its pipeline of drug candidates to address unmet medical needs in oncology.
- Ticker
- PRLD:NASDAQ
- Asset type
- Stock
- Market cap
- $366.3M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Prelude Therapeutics Incorporated PRLD:NASDAQ stock context
This page tracks Prelude Therapeutics Incorporated's PRLD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PRLD:NASDAQ. PRLD:NASDAQ is the stock-level entry point for investors researching Prelude Therapeutics Incorporated, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Prelude Therapeutics Incorporated, trading under the ticker PRLD, is a public company based in the United States with a market capitalization of approximately $305 million. The company focuses on developing innovative therapies for cancer treatment. Prelude Therapeutics is committed to advancing its pipeline of drug candidates to address unmet medical needs in oncology.
Latest news from Prelude Therapeutics Incorporated
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Sel...
September 10, 2026
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Hi...
April 20, 2026
Prelude Therapeutics Incorporated earnings calls
Research Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated investor report
Review AI stock analysis and investor report context for PRLD:NASDAQ.
Prelude Therapeutics Incorporated company profile
View the public company page for Prelude Therapeutics Incorporated on 6ix.
Prelude Therapeutics Incorporated news
Read company news and market updates connected to Prelude Therapeutics Incorporated.
Prelude Therapeutics Incorporated investor events
Find investor webinars, events, and replay context for Prelude Therapeutics Incorporated.